Checkpoint Therapeutics Stock Probability of Future Stock Price Finishing Under 3.78

CKPT Stock  USD 3.99  0.01  0.25%   
Checkpoint Therapeutics' future price is the expected price of Checkpoint Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Checkpoint Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Checkpoint Therapeutics Backtesting, Checkpoint Therapeutics Valuation, Checkpoint Therapeutics Correlation, Checkpoint Therapeutics Hype Analysis, Checkpoint Therapeutics Volatility, Checkpoint Therapeutics History as well as Checkpoint Therapeutics Performance.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.
  
Please specify Checkpoint Therapeutics' target price for which you would like Checkpoint Therapeutics odds to be computed.

Checkpoint Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Checkpoint Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Checkpoint Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Checkpoint Therapeutics is way too risky over 90 days horizon
Checkpoint Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (27.59 M).
Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Checkpoint Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 24.0% of the company shares are held by company insiders

Checkpoint Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Checkpoint Stock often depends not only on the future outlook of the current and potential Checkpoint Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Checkpoint Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18.7 M
Cash And Short Term Investments4.9 M

Checkpoint Therapeutics Technical Analysis

Checkpoint Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Checkpoint Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Checkpoint Therapeutics. In general, you should focus on analyzing Checkpoint Stock price patterns and their correlations with different microeconomic environments and drivers.

Checkpoint Therapeutics Predictive Forecast Models

Checkpoint Therapeutics' time-series forecasting models is one of many Checkpoint Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Checkpoint Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Checkpoint Therapeutics

Checking the ongoing alerts about Checkpoint Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Checkpoint Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Checkpoint Therapeutics is way too risky over 90 days horizon
Checkpoint Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 103 K. Net Loss for the year was (51.85 M) with loss before overhead, payroll, taxes, and interest of (27.59 M).
Checkpoint Therapeutics currently holds about 30.89 M in cash with (47.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Checkpoint Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 24.0% of the company shares are held by company insiders

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.